EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early ...

BEAUFORT, S.C.--(BUSINESS WIRE)--A new analysis published by THE SAGE GROUP concludes that ALI represents a substantial market opportunity for pharmaceutical and interventional therapies. “Although ...

Among PAD patients who have undergone revascularization, a combination of rivaroxaban (Xarelto; Bayer/Janssen) and low-dose aspirin is superior to aspirin alone for the prevention of acute limb ...

Thrombolysis with such agents as urokinase, rt-PA, streptokinase (Streptase, Astra Pharmaceutical, Eatontown, NJ), and reteplase has been investigated in uncontrolled trials as a therapeutic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In contemporary practice, 1 year after peripheral ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

People who took rivaroxaban (Xarelto) after lower-extremity revascularization for peripheral artery disease (PAD) enjoyed fewer subsequent major adverse limb and cardiovascular events, according to ...

Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional ...

Atherosclerosis, the major cause of limb ischemia, is a global phenomenon. As such, attention should be directed not only to the limb at risk but to the patient as whole. Hence, modification of ...